Sesen Bio to Host Conference Call to Provide OUS Business Update
July 30 2020 - 8:00AM
Business Wire
Sesen Bio (Nasdaq: SESN), a late-stage clinical company
developing targeted fusion protein therapeutics for the treatment
of patients with cancer, today announced that Company management
will host a conference call and webcast on Friday, July 31, 2020 at
8:00 a.m. EDT to provide an Outside the US (“OUS”) and general
business update.
To participate in the conference call, please dial (844)
831-3025 (domestic) or (315) 625-6887 (international) and refer to
conference ID 2177393. The webcast can be accessed in the Investor
Relations section of the company's website at www.sesenbio.com. The
replay of the webcast will be available in the investor section of
the company’s website at www.sesenbio.com for 60 days following the
call.
About Sesen Bio
Sesen Bio, Inc. is a late-stage clinical company advancing
targeted fusion protein therapeutics for the treatment of patients
with cancer. The Company’s lead program, Vicineum™, also known as
VB4-845, is currently in a Phase 3 registration trial for the
treatment of high-risk, BCG-unresponsive non-muscle invasive
bladder cancer (NMIBC). In December 2019, the Company initiated the
BLA submission for Vicineum to the FDA under Rolling Review.
Vicineum is a locally administered targeted fusion protein composed
of an anti-EpCAM antibody fragment tethered to a truncated form of
Pseudomonas Exotoxin A for the treatment of high-risk NMIBC. For
more information, please visit the company’s website at
www.sesenbio.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200730005473/en/
Erin Clark, Vice President, Corporate Strategy & Investor
Relations ir@sesenbio.com
Sesen Bio (NASDAQ:SESN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sesen Bio (NASDAQ:SESN)
Historical Stock Chart
From Sep 2023 to Sep 2024